GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellerophon Therapeutics Inc (OTCPK:BLPH) » Definitions » Median PS Value

Bellerophon Therapeutics (Bellerophon Therapeutics) Median PS Value : $0.00 (As of May. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Bellerophon Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Bellerophon Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.532. Bellerophon Therapeutics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-05-14), Bellerophon Therapeutics's share price is $0.0563. Bellerophon Therapeutics's Median PS Value is $0.00. Therefore, Bellerophon Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Bellerophon Therapeutics's Median PS Value or its related term are showing as below:

BLPH's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.69
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Bellerophon Therapeutics Median PS Value Historical Data

The historical data trend for Bellerophon Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellerophon Therapeutics Median PS Value Chart

Bellerophon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bellerophon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bellerophon Therapeutics's Median PS Value

For the Biotechnology subindustry, Bellerophon Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellerophon Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellerophon Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Bellerophon Therapeutics's Price-to-Median-PS-Value falls into.



Bellerophon Therapeutics Median PS Value Calculation

Bellerophon Therapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.532*0
=0.00

10-Year Median PS Ratio is 0.
Bellerophon Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.532.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellerophon Therapeutics  (OTCPK:BLPH) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Bellerophon Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.0563/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellerophon Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Bellerophon Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059
Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.
Executives
Puissance Life Science Opportunities Fund Vi 10 percent owner 950 THIRD AVENUE, FL 25, NEW YORK NY 10022
Naseem Amin director 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Mary Ann Cloyd director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Theodore T Wang director C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott P Bruder director C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Crispin Teufel director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Puissance Capital Fund (gp) Llc 10 percent owner 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Parag Suresh Shah officer: VP of Business Operations C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059
Martin Dekker officer: See Remarks 53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827
Peter Fernandes officer: See Remarks PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Bobae Kim officer: VP Reg. Affairs & Quality 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Nicholas Laccona officer: Controller, (PFO & PAO) 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Steven B Klinsky 10 percent owner C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Capital, L.l.c. 10 percent owner 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Investments Ii, Llc 10 percent owner 787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019

Bellerophon Therapeutics (Bellerophon Therapeutics) Headlines